Bioconjugate & ADC Technology Transfer

Abzena delivers a comprehensive approach to biologics technology transfer, ensuring a robust & consistent manufacturing process from clinical through commercial.

Fast-track your tech transfer with Abzena.

Through a comprehensive bioconjugation technology transfer process, Abzena delivers a reliable scale-up model that ensures a robust and consistent manufacturing process from clinical to commercial scale.

We work closely with your team to de-risk the pathway to commercialization, confirm manufacturability, and deliver high-quality bioconjugates to patients through our integrated bioconjugation services.

Our risk-based approach captures process knowledge and analytical data across each phase of bioconjugate development. This ensures seamless transfer of bioconjugate technologies and ADC technology into full-scale manufacturing while incorporating regulatory feedback for long-term program success.

Our Tech Transfer Approach

Abzena’s prospective bioconjugation approach ensures the seamless transfer of all essential information and that each plan aligns precisely with the needs to your program.

Adaptable to each project, our team of scientific leaders applies deep expertise in bioconjugates, chemistry and problem-solving. We can deliver complex projects within narrow timelines through maintaining effective communication and transparency of data throughout each transfer phase.

Committed to quality, we ensure continued supply of your products to your predefined specifications. All processes within our bioconjugation services follow cGMP manufacturing regulations, supporting reliable scale-up and long-term performance of advanced bioconjugate technologies.

Bioconjugates, ADCs & Chemistry CRO+CDMO - Abzena

Your Dedicated Project Team

Your project will have a dedicated team appropriate to its requirements. They work relentlessly to ensure the efficient and responsible delivery of your transfer. Each team consists of a lead for:

Having a tech transfer plan is easier than you think

It is never too early to start researching which CDMO is the best partner for your biologics program. Technology transfers may not be easy, starting a conversation with Abzena’s scientific team is. We are ready to help move your medicine forward.

Bioconjugate & ADC Technology Transfer FAQs

How does Abzena manage technology transfer for bioconjugate development?

Abzena uses a structured, risk-based bioconjugation transfer process that captures data, analytics, and process knowledge to ensure reliable bioconjugate development from lab to GMP scale.

What role does bioconjugate chemistry play in ADC technology?

Bioconjugate chemistry determines how antibodies are linked to cytotoxic or functional payloads. It is key to achieving stable, reproducible ADC technologies with consistent performance.

How does Abzena ensure quality during technology transfer?

All bioconjugation services follow cGMP standards and validated analytical controls, ensuring each transferred process meets predefined specifications for quality and compliance.

What bioconjugate technologies does Abzena support?

Abzena supports a full range of bioconjugate technologies. This includes ADC technology, and novel conjugation methods for antibody-oligonucleotides (AOCs), peptides and other therapeutic modalities.

Let's move medicine forward.

Our team collaborates with you and uses deep scientific and technical know-how to find the best solutions using the right technologies to transfer your program with a constant commitment to quality.